125 related articles for article (PubMed ID: 2713222)
1. Substantial rise in sparteine metabolic ratio during haloperidol treatment.
Gram LF; Debruyne D; Caillard V; Boulenger JP; Lacotte J; Moulin M; Zarifian E
Br J Clin Pharmacol; 1989 Feb; 27(2):272-5. PubMed ID: 2713222
[TBL] [Abstract][Full Text] [Related]
2. Sparteine oxidation is practically abolished in quinidine-treated patients.
Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
[TBL] [Abstract][Full Text] [Related]
3. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Nielsen MD; Brøsen K; Gram LF
Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
[TBL] [Abstract][Full Text] [Related]
4. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
[TBL] [Abstract][Full Text] [Related]
5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
6. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
Kaneko K; Atsumi T; Miyataka T
Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
9. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
[TBL] [Abstract][Full Text] [Related]
11. Sparteine oxidation polymorphism: a family study.
Brøsen K; Otton SV; Gram LF
Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
[TBL] [Abstract][Full Text] [Related]
12. Serum haloperidol concentration and clinical response in schizophrenia.
Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
[TBL] [Abstract][Full Text] [Related]
13. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
Brøsen K
Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
15. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
[TBL] [Abstract][Full Text] [Related]
17. Influence of the defective metabolism of sparteine on its pharmacokinetics.
Eichelbaum M; Spannbrucker N; Dengler HJ
Eur J Clin Pharmacol; 1979 Sep; 16(3):189-94. PubMed ID: 499319
[TBL] [Abstract][Full Text] [Related]
18. The influence of enzyme induction on polymorphic sparteine oxidation.
Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
[TBL] [Abstract][Full Text] [Related]
19. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
20. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
